Apnimed’s obstructive sleep apnea drug reduced breathing interruptions in a Phase 3 clinical trial. The once-nightly pill, which is based on research from Brigham and Women’s Hospital, activates muscles that keep the upper airway open during sleep.
The post Sleep Apnea Relief in a Pill: Apnimed Drug’s Phase 3 Data Set Stage for FDA Submission appeared first on MedCity News.
